Tharimmune (THAR) Stock Price, News & Analysis

Company Overview

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Key Stats

• Today's Range: $2.21 to $2.35
• 50-Day Range: $1.85 to $2.94
• 52-Week Range: $0.95 to $9.08
• Volume: 579,149 shs
• Average Volume: 1.48 million shs
• Market Capitalization: $84.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Tharimmune Stock Analysis - MarketRank™

Tharimmune scored higher than 1% of companies evaluated by MarketBeat, and ranked 833rd out of 836 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Tharimmune has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Tharimmune has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tharimmune is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tharimmune is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tharimmune has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for THAR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tharimmune does not currently pay a dividend.

Dividend Growth

Tharimmune does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Tharimmune has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Finance companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Tharimmune this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tharimmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.70% of the stock of Tharimmune is held by insiders.

Percentage Held by Institutions

1.16% of the stock of Tharimmune is held by institutions.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Financial Services
• Sub-Industry: Multi-Sector Holdings
• Current Symbol: NASDAQ:THAR
• Previous Symbol: NASDAQ:THAR
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -588.45%
• Return on Assets: -264.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.98
• Quick Ratio: 4.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.68 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 37,730,000
• Free Float: 35,202,000
• Market Cap: $84.14 million
• Optionable: Not Optionable
• Beta: 1.43